Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | TOP2A | P11388 | 8/20 | 0.43 |
| ▸ | TOP2B | Q02880 | 6/20 | 0.43 |
| ▸ | TOP1 | P11387 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13341765 | 1.00 | CYP3A4 (0.58) | CYP3A4ALDH1A1POLBCHRM2CHRM1 | |
| SCHEMBL3549144 | 1.00 | CYP3A4 (0.58) | CYP3A4ALDH1A1POLBCHRM2CHRM1 | |
| SCHEMBL3551445 | 0.91 | ALDH1A1 (0.57) | CYP3A4ALDH1A1POLBCHRM2CHRM1 | |
| SCHEMBL3551443 | 0.91 | ALDH1A1 (0.57) | CYP3A4ALDH1A1POLBCHRM2CHRM1 | |
| SCHEMBL2080669 | 0.88 | CYP3A4 (0.64) | CYP3A4ALDH1A1POLBCHRM2CHRM1 | |
| SCHEMBL2080667 | 0.88 | CYP3A4 (0.64) | CYP3A4ALDH1A1POLBCHRM2CHRM1 | |
| SCHEMBL3556611 | 0.88 | CYP3A4 (0.47) | CYP3A4ALDH1A1POLBCHRM2CHRM1 | |
| SCHEMBL3556609 | 0.88 | CYP3A4 (0.47) | CYP3A4ALDH1A1POLBCHRM2CHRM1 | |
| SCHEMBL2670591 | 0.88 | CYP3A4 (0.47) | CYP3A4ALDH1A1POLBCHRM2CHRM1 | |
| SCHEMBL2670137 | 0.88 | CYP3A4 (0.47) | CYP3A4ALDH1A1POLBCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1669354-B1 | 8-CYANOQUINOLONECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1669354-B1 | 8-CYANOQUINOLONECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-03-20 | — | — | EP | disclosed |
| US-7723524-B2 | 8-cyanoquinolonecarboxylic acid derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-05-25 | — | — | US | disclosed |
| US-7723524-B2 | 8-cyanoquinolonecarboxylic acid derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-05-25 | — | — | US | disclosed |
| US-7723524-B2 | 8-cyanoquinolonecarboxylic acid derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-05-25 | — | — | US | disclosed |
| US-20080255190-A1 | 8-Cyanoquinolonecarboxylic Acid Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080255190-A1 | 8-Cyanoquinolonecarboxylic Acid Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080255190-A1 | 8-Cyanoquinolonecarboxylic Acid Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-10-16 | — | — | US | disclosed |
| EP-1669354-A1 | 8-CYANOQUINOLONECARBOXYLIC ACID DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255190-A1 | 8-Cyanoquinolonecarboxylic Acid Derivative | QPCT, ASNS, C3AR1 | CYP3A4 1439/4885ALDH1A1 2947/4885POLB 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.